Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026

Complement-mediated diseases arise from overactivation or dysfunction of the complement system, a part of the innate immune system.Trial DataThe Phase 1 study results demonstrated complete and sustained inhibition of terminal complement at a 300 mg dose, with a safety profile consistent with other subcutaneous biologics.Complete and sustained inhibition of ex vivo hemolytic activity demonstrates clinically effective blockade of terminal complement.In the study, RLYB116 showed promising pharmacokinetic and p ...